Hafnia alvei: Difference between revisions
From IDWiki
Hafnia alvei
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
* Reliably susceptible to [[imipenem]], [[ciprofloxacin]], [[piperacillin]], [[cotrimoxazole]][[CiteRef::gunthard1996cl]][[CiteRef::ramos2000ex]] |
* Reliably susceptible to [[imipenem]], [[ciprofloxacin]], [[piperacillin]], [[cotrimoxazole]][[CiteRef::gunthard1996cl]][[CiteRef::ramos2000ex]] |
||
* May be susceptible to [[ceftriaxone]] and [[ceftazidime]] |
* May be susceptible to [[ceftriaxone]] and [[ceftazidime]], but may have inducible resistance[[lancelevee2007an]] |
||
** Unreliably susceptible to cephalothin and [[amoxicillin-clavulanic acid]] |
|||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
||
Revision as of 12:44, 20 June 2025
Background
- Gram-negative bacillus in the genus Hafnia
- Rare cause of disease in humans
Clinical Manifestations
- Can cause bacteremia, gastroenteritis, meningitis, pneumonia, nosocomial wound infections, hepatobiliary infections, psoas abscess, prosthetic valve endocarditis, and endophthalmitis12
Management
- Reliably susceptible to imipenem, ciprofloxacin, piperacillin, cotrimoxazole12
- May be susceptible to ceftriaxone and ceftazidime, but may have inducible resistancelancelevee2007an
- Unreliably susceptible to cephalothin and amoxicillin-clavulanic acid
References
- ^ H. Gunthard, A. Pennekamp. Clinical Significance of Extraintestinal Hafnia alvei Isolates from 61 Patients and Review of the Literature. Clinical Infectious Diseases. 1996;22(6):1040-1045. doi:10.1093/clinids/22.6.1040.
